Congenital cholesteatoma (epidermoid) is a benign mass originating from epidermal inclusion present since birth. It originates from trapped epidermoid tissue remnants during normal development of the middle ear mucoperiosteum in the embryonic period. Clinically, it appears as a white/opaque mass behind an intact tympanic membrane — this appearance is the key differentiating feature from acquired cholesteatoma, which has a retraction pocket. It presents in childhood (usually ages 5-10) with unilateral conductive hearing loss. CT shows a non-dependent (gravity-independent) soft tissue mass in the middle ear. Marked bright signal on DWI on MRI is pathognomonic — restricted diffusion reflects keratin content. Treatment is surgical excision, recurrence risk is 5-15%, and postoperative follow-up with non-EPI DWI is the standard approach.
Age Range
2-15
Peak Age
5
Gender
Male predominant
Prevalence
Uncommon
Congenital cholesteatoma develops from epidermoid tissue remnants trapped in the middle ear cavity during the embryonic period. According to Michaels' epidermoid formation theory, a transient epidermoid structure exists in the middle ear between the 10th-33rd weeks of fetal development and normally undergoes resorption. If resorption is incomplete, epidermoid tissue remnants remain and grow over time to form a congenital cholesteatoma. The lesion is lined by squamous epithelium and produces keratin — this keratin accumulation is responsible for lesion growth. Keratin lamellae (dense cylindrical layers) impede free diffusion of water molecules — this is the physical basis for restricted diffusion (bright signal) and low ADC values on MRI DWI. The non-dependent soft tissue appearance on CT indicates that the mass is not affected by gravity, meaning it has solid/semi-solid content (not serous fluid). The mass causes conductive hearing loss by compressing the ossicular chain. Bone erosion may develop in late stages but is not as aggressive as acquired cholesteatoma.
Marked bright signal on DWI with diffusion restriction confirmed by low ADC values on ADC map is the pathognomonic finding for cholesteatoma. Keratin content impedes water diffusion. This finding differentiates cholesteatoma from all other middle ear and petrous apex lesions (cholesterol granuloma, effusion, meningioma, schwannoma — none of these show DWI restriction).
A gravity-independent (non-dependent) soft tissue mass in the middle ear cavity is seen on CT. The lesion typically occupies the anterosuperior quadrant (Potsic Stage I). It has round or oval morphology, smooth margins, and homogeneous soft tissue density. It may compress and displace the ossicular chain. In advanced stages, it may fill the entire middle ear cavity. Ossicular erosion appears later and less aggressive than acquired type. Tympanic membrane integrity should be confirmed.
Report Sentence
A ___ mm non-dependent, smooth-marginated soft tissue mass in the anterosuperior quadrant of the middle ear is identified; congenital cholesteatoma should be the primary consideration in the presence of intact tympanic membrane.
The lesion shows marked bright signal on DWI with low ADC values (typically <0.8 × 10⁻³ mm²/s) on ADC map confirming diffusion restriction. This finding is pathognomonic for cholesteatoma (congenital and acquired). Non-EPI DWI (HASTE DWI, PROPELLER DWI) produces fewer susceptibility artifacts in the temporal bone region than standard EPI DWI and is preferred. DWI is also the gold standard method for postoperative residual/recurrence follow-up — residual cholesteatoma 3mm and above can be detected.
Report Sentence
Marked diffusion restriction is identified in the lesion on DWI (ADC: ___ × 10⁻³ mm²/s), pathognomonic for cholesteatoma.
The lesion appears hypointense or isointense on T1-weighted sequences (relative to brain parenchyma). No enhancement is seen on post-contrast series — reflecting the avascular content of the lesion. T1 hypointensity + no enhancement is critical in differential diagnosis from cholesterol granuloma (T1 hyperintense) and solid tumors like schwannoma/meningioma (marked enhancement). In postoperative follow-up, post-contrast T1 is used to differentiate granulation tissue (enhances) from residual cholesteatoma (no enhancement).
Report Sentence
The lesion is T1 hypointense with no enhancement on post-contrast series; consistent with an avascular lesion (cholesteatoma).
The lesion demonstrates hyperintense signal on T2-weighted sequences. T2 hyperintensity reflects the water content and free fluid compartments between keratin lamellae in the lesion. T2 3D CISS/FIESTA sequences show the size, margins, and relationship to adjacent structures (ossicular chain, facial nerve canal, labyrinth) in detail with high spatial resolution.
Report Sentence
The lesion demonstrates hyperintense signal on T2-weighted sequences; its relationship to the ossicular chain/facial nerve canal/labyrinth should be evaluated.
Ossicular chain erosion may be seen in advanced congenital cholesteatoma. The long process of incus and stapes superstructure are most commonly affected. Ossicular chain integrity, displacement, and early erosion findings are evaluated on CT bone window reconstructions. However, bone erosion develops later and is more limited compared to acquired cholesteatoma.
Report Sentence
Erosion of the long process of incus/stapes superstructure is identified in the ossicular chain, consistent with bone loss related to cholesteatoma pressure.
Criteria
Cholesteatoma limited to single quadrant (usually anterosuperior). Ossicular chain and other structures intact.
Distinct Features
Most common stage. Small white mass behind tympanic membrane on otoscopy. Complete surgical excision easy.
Criteria
Stage II: multiple quadrant involvement. Stage III: ossicular chain erosion or mastoid extension.
Distinct Features
Hearing loss more prominent. Surgery more complex, ossicular reconstruction may be needed.
Criteria
Cholesteatoma extends to labyrinth and/or facial nerve canal. Most advanced stage.
Distinct Features
SNHL and/or facial nerve palsy may be added. Surgery most complex, facial nerve preservation critical.
Distinguishing Feature
Cholesterol granuloma: T1 AND T2 hyperintense (T1 hypointense in cholesteatoma). Cholesterol granuloma no DWI restriction. Cholesterol granuloma at petrous apex, cholesteatoma in middle ear.
Distinguishing Feature
SCC: aggressive bone destruction + marked enhancement (no enhancement in cholesteatoma). SCC adult, cholesteatoma childhood. SCC DWI variable, cholesteatoma DWI always bright.
Distinguishing Feature
Meningioma: intense homogeneous enhancement + dural tail (no enhancement in cholesteatoma). Meningioma DWI usually not bright, cholesteatoma DWI bright.
Urgency
routineManagement
surgicalBiopsy
Not NeededFollow-up
12-monthSurgical excision is the standard treatment. Performed with tympanoplasty + ossicular reconstruction (if needed). Surgical extent is determined by Potsic staging. Recurrence rate 5-15% (20-30% in acquired type). Annual postoperative residual/recurrence follow-up with non-EPI DWI — MRI follow-up is the preferred approach instead of second-look surgery. Residual cholesteatoma 3mm and above can be detected by non-EPI DWI. Sensitivity 82-100%, specificity 88-100%. Early diagnosis and surgery ensure facial nerve and hearing preservation.
Surgical excision is the standard treatment. It is performed with tympanoplasty. Recurrence risk is 5-15%. Postoperative non-EPI DWI is used for residual/recurrence follow-up. Early diagnosis is critical for ossicular chain and facial nerve preservation.